Skip to main content
  • COVID-19
    • COVID-19 vaccines and cancer
      • FAQs
      • FAQs in-language
      • SerOzNET Study
    • COVID-19 information for people affected by cancer
      • Managing your cancer care in the context of COVID-19
      • Looking after your mental wellbeing
      • Canada
      • Ireland
      • UK
      • USA
    • COVID-19 information for children and young people with cancer
    • Cancer Won’t Wait
    • Cancer and COVID-19 - what it means for our Mob
      • COVID-19 vaccines: Information for Aboriginal and Torres Strait Islander people affected by cancer
      • Act early for our Mob's health
    • Guidance for health professionals
      • Diagnosis
      • Treatment
      • Surgery
      • Medical oncology
      • Radiation oncology
      • Primary care
      • Telehealth
      • Clinical trials
      • Follow-up care
      • Supportive and Palliative care
      • Cancer care for cancer patients with COVID-19
      • COVID-19 vaccines and cancer
      • Recovery
    • Research articles
      • Review articles
      • Data articles
      • Recommendations articles
      • Shared experience articles
      • COVID-19 vaccines and cancer articles
    • Cancer care in the time of COVID-19: A conceptual framework
    • Optimal cancer care during the COVID-19 pandemic: the Principles
    • The impact of COVID-19 on cancer services
    • COVID-19 Recovery: Implications for cancer care
      • Expanded use of telehealth
      • Changes to prevention and early detection
      • Virtual multidisciplinary team meetings
      • Modifications to treatment schedules
      • Hypofractionated radiotherapy
      • Oncology hospital in the home
      • Responsive patient support
      • Innovative care and hospital infrastructure models
      • Shared follow-up and survivorship care
      • Supportive and palliative care
      • Cancer research and clinical trials
      • Collaboration in the oncology sector and data sharing
      • Acknowledgements
  • About us
    • Organisational structure
    • Accountability and reporting
      • Annual reports
    • Who we work with
      • Roles & functions
      • Advisory Council
      • Advisory groups
      • Consumer engagement
      • Government cancer control organisations
    • Information publication scheme
      • Information publication scheme plan
      • Freedom of information act
        • The FOI request process
      • FOI disclosure log
    • Reconciliation action plan
    • Employment opportunities
  • News and media
    • News
    • Subscribe to our eNewsletter
  • Contact us
Cancer Australia
Choose Language
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • Home
  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives
  • Home
  • Cancer types
    • Bladder cancer
    • Bowel cancer
    • Brain cancer
    • Breast cancer
    • Breast cancer in men
    • Breast cancer in young women
    • Cervical cancer
    • Children’s cancer
    • Endometrial cancer
    • Fallopian cancer
    • Gestational trophoblastic disease
    • Gynaecological cancers
    • Head and neck cancer
    • Kidney cancer
    • Leukaemia
    • Liver cancer
    • Lung cancer
    • Lymphoma
    • Melanoma
    • Mesothelioma cancer
    • Myeloma
    • Neuroendocrine tumours
    • Oesophageal cancer
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer
    • Sarcoma
    • Stomach cancer
    • Testicular cancer
    • Thyroid cancer
    • Unknown primary cancer
    • Uterine sarcoma
    • Vaginal cancer
    • Vulvar cancer
  • Impacted by Cancer
    • What is cancer
    • Physical changes
    • Treatment
    • Keeping healthy
    • Emotions
    • Family and relationships
    • Living with cancer
    • Lynch Syndrome
  • Awareness
    • Your cancer risk
    • Screening
    • Interactive body map
  • Research
    • Cancer Research in Australia
    • Data and statistics
    • Australian Clinical Trials
    • Support for cancer clinical trials
    • Grants and funding
  • Resources
    • Cancer Australia Publications
    • Clinical Practice Guidelines
    • Position statements
    • Resources in other languages
    • Cancer Australia websites
    • Cancer risk online assessment tools
    • Other tools and resources
    • Podcasts
    • Cancer support organisations
    • Glossary
  • Clinicians hub
    • GP guides and resources
    • Guidelines by cancer type
    • Optimal Care pathways
    • Working with Aboriginal and Torres Strait Islander people
    • Multidisciplinary care
    • Psychosocial care
    • Follow-up care
    • Family cancer clinics
    • Cancer Learning
    • Consumer engagement
  • Key initiatives
    • For Aboriginal and Torres Strait Islander people
    • Australian Cancer Plan
    • Australian Brain Cancer Mission
    • Lung Cancer Screening
    • National Pancreatic Cancer Roadmap
    • Campaigns & events
    • Jeannie Ferris Recognition Award

Cancer of unknown primary

unknown-mm cancer-types/unknown-primary-cancer/overview
    • Home
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Treatment
    • Finding support
    • Clinical trials
    • Health professionals
    • Home
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Treatment
    • Finding support
    • Clinical trials
    • Health professionals
  1. Home
  2. Statistics
Loading...

Cancer of unknown primary site in Australia statistics

  • Printer-friendly version
  • A|A

The following material has been sourced from the Australian Institute of Health and Welfare

Cancer of unknown primary site incorporates ICD-10 cancer codes: Incidence C80 (Malignant neoplasm without specification of site); mortality C77–C80 (C77: Secondary and unspecified malignant neoplasm of lymph nodes, C78: Secondary malignant neoplasm of respiratory and digestive organs, C79: Secondary malignant neoplasm of other and unspecified sites; C80: Malignant neoplasm without specification of site), C97 (Malignant neoplasms of independent primary multiple sites). 


Estimated number of new cases of cancer of unknown primary site diagnosed in 2022

2,596 = male 1,452 males + Female icon PNG 1,144 females


Estimated % of all new cancer cases diagnosed in 2022

1.6%


Estimated number of deaths from cancer of unknown primary site in 2022

2,596 = male 1,416 males + Female icon PNG 1,180 females


Estimated % of all deaths from cancer in 2022

5.2%


Chance of surviving at least 5 years (2014–2018)

13%


People living with cancer of unknown primary site at the end of 2017 (diagnosed in the 5 year period 2013 to 2017)

2,734


New cases

In 2018, there were 2,805 new cases of cancer of unknown primary site diagnosed in Australia (1,525 males and 1,280 females). In 2022, it is estimated that 2,596 new cases of cancer of unknown primary site will be diagnosed in Australia (1,452 males and 1,144 females). In 2022, it is estimated that a person has a 1 in 138 (or 0.72%) risk of being diagnosed with cancer of unknown primary site by the age of 85 (1 in 114 or 0.88% for males and 1 in 178 or 0.56% for females).

Figure 1. Estimated cancer incidence in Australia, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for the most common cancers diagnosed can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence) 

In 2018, the age-standardised incidence rate was 9.1 cases per 100,000 persons (11 for males and 7.5 for females). In 2022, it is estimated that the age-standardised incidence rate will be 7.4 cases per 100,000 persons (9.2 for males and 5.8 for females). The incidence rate for cancer of unknown primary site is expected to increase with age.

figure 2 unknown primary

Figure 2. Age-standardised incidence rates for cancer of unknown primary site, 1982 to 2018, by sex

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for cancer of unknown primary site over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence) 

The number of new cases of cancer of unknown primary site diagnosed increased from 2,141 (1,119 males and 1,022 females) in 1982 to 2,805 in 2018. Over the same period, the age-standardised incidence rate decreased from 18 cases per 100,000 persons (21 for males and 15 for females) in 1982 to 9.1 cases per 100,000 in 2018.

Deaths 

In 2020, cancer of unknown primary site was the sixth most common cause of cancer death in Australia. It is estimated that it will remain the sixth most common cause of death from cancer in 2022.

In 2020, there were 2,633 deaths from cancer of unknown primary site in Australia (1,427 males and 1,206 females). In 2022, it is estimated that there will be 2,596 deaths (1,416 males and 1,180 females). In 2022, it is estimated that a person has a 1 in 139 (or 0.72%) risk of dying from cancer of unknown primary site by the age of 85 (1 in 120 or 0.83% for males and 1 in 165 or 0.61% for females).

Figure 3. Estimated cancer mortality in Australia, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for the most common causes of cancer death can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality) 

In 2020, the age-standardised mortality rate was 7.9 deaths per 100,000 persons (9.5 for males and 6.5 for females). In 2022, it is estimated that the age-standardised mortality rate will be 7.3 deaths per 100,000 persons (8.9 for males and 5.9 for females). The mortality rate for cancer of unknown primary site is expected to increase with age.

figure 4 unknown primary

Figure 4. Age-standardised mortality rates for cancer of unknown primary site, 1982 to 2020, by sex

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for cancer of unknown primary site over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality) 

The number of deaths from cancer of unknown primary site increased from 1,202 (609 males and 593 females) in 1982 to 2,633 in 2020. Over the same period, the age-standardised mortality rate remained similar from 10 deaths per 100,000 persons (12 for males and 8.9 for females) in 1982 to 7.9 deaths per 100,000 in 2020. 

Survival 

In 2014–2018, individuals diagnosed with cancer of unknown primary site had a 13% chance (16% for males and 10% for females) of surviving for five years compared to their counterparts in the general Australian population. Between 1989–1993 and 2014–2018, five-year relative survival for cancer of unknown primary site improved from 6.2% to 13%. 

Figure 5. 5-year relative survival for cancer of unknown primary site, 1989–1993 to 2014–2018, by sex

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about 5-year relative survival rates for cancer of unknown primary site over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Relative survival rate’ section (https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/5-year-relative-survival) 

Prevalence 

At the end of 2017, there were 936 people living who had been diagnosed with cancer of unknown primary site that year, 2,734 people living who had been diagnosed with cancer of unknown primary site in the previous 5 years (from 2013 to 2017) and 7,039 people living who had been diagnosed with cancer of unknown primary site in the previous 36 years (from 1982 to 2017).

For more information, see Unknown primary site (cancer of) on the NCCI website

The National Cancer Control Indicators (NCCI) are a set of indicators across the continuum of cancer care, from Prevention and Screening through to Diagnosis, Treatment, Psychosocial care, Research and Outcomes.  The NCCI website allows users to see visual representations of data on each indicator through interactive charts. 

  • Last Updated
  • Relevant Links
updated: 22 September 2022 - 3:12pm
American Cancer Society, Cancer of unknown primary
National Cancer Institute (US), Carcinoma of unknown primary treatment (PDQ®), patient version
Australian Cancer Trials

Related information

What is cancer?
What is cancer?

Cancer is a disease of the cells, which are the body’s basic building blocks.

Treatment and side effects
Treatment and side effects

The treatment that your doctors recommend will depend on the type of cancer you have, how advanced it is, and other personal factors.

Living with cancer
Living with cancer

A diagnosis of cancer marks the beginning of a journey full of emotional, psychological, physical and practical challenges.

Life after cancer
Life after cancer

While looking forward to finishing their cancer treatment and getting on with life, for some people, the end of treatment can also be a confusing or worrying time.

A-Z List of Cancer Types

Information on more than 70 types of cancer

  • Bladder cancer
  • Bowel cancer
  • Brain cancer
  • Breast cancer
  • Breast cancer in men
  • Breast cancer in young women
  • Cervical cancer
  • Children's Cancer
  • Endometrial cancer
  • Fallopian cancer
  • Gestational trophoblastic disease
  • Gynaecological cancers
  • Head and neck cancer
  • Kidney cancer
  • Leukaemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Melanoma of the skin
  • Mesothelioma cancer
  • Myeloma
  • Neuroendocrine tumours
  • Oesophageal cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Sarcoma
  • Stomach cancer
  • Testicular cancer
  • Thyroid cancer
  • Unknown primary
  • Uterine sarcoma
  • Vaginal cancer
  • Vulval cancer

About Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

Freecall 1800 624 973
+61 2 9357 9400

Locked Bag 3, Strawberry Hills
NSW 2012

Navigation

  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives

Contact us

* Denotes mandatory fields
 

By submitting this form, you accept the Cancer Australia privacy policy.

  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
  • Sitemap
Copyright © 2023 - Cancer Australia